Back to top
more

Principia Biopharma Inc. (PRNB)

(Delayed Data from NSDQ)

$30.40 USD

30.40
67,574

+1.38 (4.76%)

Updated May 3, 2019 04:00 PM ET

After-Market: $30.41 (%) 5:22 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.68%
2Buy17.55%
3Hold9.21%
4Sell4.93%
5Strong Sell2.36%
S&P50010.96%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

NA Value NA Growth NA Momentum NA VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

NA

Industry: NA

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Brokerage Reports

0 items in cart

[PRNB]

Reports for Purchase

Showing records 1 - 20 ( 23 total )

Industry: Medical - Biomedical and Genetics

Record: 1

09/29/2020

Company Report

Pages: 6

Dropping Coverage on Sanofi Acquisition

Provider: H.C. Wainwright & Co., Inc.

Analyst: PANTGINIS J

Price: 25.00

Research Provided by a Third Party

Industry: Medical - Biomedical and Genetics

Record: 2

08/17/2020

Company Report

Pages: 6

Monday Morning Surprise...Well Not Really; Sanofi Acquires Principia; Downgrade to Neutral

Provider: H.C. Wainwright & Co., Inc.

Analyst: PANTGINIS J

Price: 25.00

Research Provided by a Third Party

Industry: Medical - Biomedical and Genetics

Record: 3

08/07/2020

Company Report

Pages: 7

Moons Are Really Aligning to Us; PT Upped to $108

Provider: H.C. Wainwright & Co., Inc.

Analyst: PANTGINIS J

Price: 25.00

Research Provided by a Third Party

Industry: Medical - Biomedical and Genetics

Record: 4

06/23/2020

Daily Note

Pages: 4

Sanofi Starts MS Phase 3 Program; Principia About to Cash a $50M Check

Provider: H.C. Wainwright & Co., Inc.

Analyst: PANTGINIS J

Price: 10.00

Research Provided by a Third Party

Industry: Medical - Biomedical and Genetics

Record: 5

06/15/2020

Company Report

Pages: 8

More Evidence That PEGASUS Should Fly

Provider: H.C. Wainwright & Co., Inc.

Analyst: PANTGINIS J

Price: 25.00

Research Provided by a Third Party

Industry: Medical - Biomedical and Genetics

Record: 6

06/12/2020

Company Report

Pages: 7

ITP Update Confirms Our Confidence in Rilzabrutinib

Provider: H.C. Wainwright & Co., Inc.

Analyst: PANTGINIS J

Price: 25.00

Research Provided by a Third Party

Industry: Medical - Biomedical and Genetics

Record: 7

04/24/2020

Company Report

Pages: 8

Sanofi Delivers on MS Phase 2b Data as Broad Phase 3Program About to Get Cranking.

Provider: H.C. Wainwright & Co., Inc.

Analyst: PANTGINIS J

Price: 25.00

Research Provided by a Third Party

Industry: Medical - Biomedical and Genetics

Record: 8

04/09/2020

Company Report

Pages: 7

Reiterate Core Name for Post-COVID-19 Rebound; Takeout in the Future?

Provider: H.C. Wainwright & Co., Inc.

Analyst: PANTGINIS J

Price: 25.00

Research Provided by a Third Party

Industry: Medical - Biomedical and Genetics

Record: 9

03/30/2020

Daily Note

Pages: 94

Market Shudders But We See Names to Outperform.

Provider: H.C. Wainwright & Co., Inc.

Analyst: Research Department

Price: 150.00

Research Provided by a Third Party

Industry: Medical - Biomedical and Genetics

Record: 10

03/11/2020

Company Report

Pages: 7

2019 Results; Continued Strong Fundamentals in Volatile Markets

Provider: H.C. Wainwright & Co., Inc.

Analyst: PANTGINIS J

Price: 25.00

Research Provided by a Third Party

Industry: Medical - Biomedical and Genetics

Record: 11

02/06/2020

Company Report

Pages: 6

Continued Evidence That the Drugs Work; Target Increased to $70

Provider: H.C. Wainwright & Co., Inc.

Analyst: PANTGINIS J

Price: 25.00

Research Provided by a Third Party

Industry: Medical - Biomedical and Genetics

Record: 12

01/28/2020

Company Report

Pages: 7

Success Also Breeds Naysayers and Inaccuracies; Reiterate Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: PANTGINIS J

Price: 25.00

Research Provided by a Third Party

Industry: Medical - Biomedical and Genetics

Record: 13

01/09/2020

Company Report

Pages: 6

Further BTK Expansion; Sanofi''s Important MS Data Expected This Quarter; Target Tweaked to $62

Provider: H.C. Wainwright & Co., Inc.

Analyst: PANTGINIS J

Price: 25.00

Research Provided by a Third Party

Industry: Medical - Biomedical and Genetics

Record: 14

01/07/2020

Company Report

Pages: 7

Rilzabrutinib Expansion Continues; Preliminary 2020 Outlook; Target Upped to $63

Provider: H.C. Wainwright & Co., Inc.

Analyst: PANTGINIS J

Price: 25.00

Research Provided by a Third Party

Industry: Medical - Biomedical and Genetics

Record: 15

12/09/2019

Company Report

Pages: 8

PRN1008 ITP Data Shine at ASH

Provider: H.C. Wainwright & Co., Inc.

Analyst: PANTGINIS J

Price: 25.00

Research Provided by a Third Party

Industry: Medical - Biomedical and Genetics

Record: 16

11/06/2019

Company Report

Pages: 6

3Q19 Results; Expect Strong ITP Update at ASH

Provider: H.C. Wainwright & Co., Inc.

Analyst: PANTGINIS J

Price: 25.00

Research Provided by a Third Party

Industry: Medical - Biomedical and Genetics

Record: 17

10/21/2019

Company Report

Pages: 7

Early and Impressive ITP Data as Well as Topping Off Coffers; Target Increased to $57

Provider: H.C. Wainwright & Co., Inc.

Analyst: PANTGINIS J

Price: 25.00

Research Provided by a Third Party

Industry: Medical - Biomedical and Genetics

Record: 18

10/10/2019

Company Report

Pages: 6

Consistency Is the Message of the Day for PV Efficacy

Provider: H.C. Wainwright & Co., Inc.

Analyst: PANTGINIS J

Price: 25.00

Research Provided by a Third Party

Industry: Medical - Biomedical and Genetics

Record: 19

10/08/2019

Company Report

Pages: 10

ValuEngine Detailed Valuation Report for PRNB

Provider: ValuEngine, Inc

Analyst: Research Department

Price: 25.00

Research Provided by a Third Party

Industry: Medical - Biomedical and Genetics

Record: 20

09/23/2019

Company Report

Pages: 6

Don''t Forget; PV and ITP Key Data Catalysts Not Too Far Off

Provider: H.C. Wainwright & Co., Inc.

Analyst: PANTGINIS J

Price: 25.00

Research Provided by a Third Party
// eof